MIDAS 2 (Modafinil in Debilitating Fatigue After Stroke 2)

The MIDAS2 study is looking for people who have severe persisting fatigue after Stroke. The study will test whether the wakefulness medication called ‘Modafinil’ taken for 56 days is safe and can alleviate Stroke-related fatigue in a much larger group of Stroke survivors.

There are currently 18 hospitals across Australia participating in the study.

---

Fatigue:

• affects up to 70% of Stroke survivors
• defined as ‘a feeling of early exhaustion with weariness, lack of energy and aversion to effort that develops during physical or mental activity and is usually not improved by rest’.

Participants will receive either 200 mg of modafinil or placebo (an identical tablet with no active ingredients). There is a 50% chance of being in either of these groups.

---

Who can participate?

You may be eligible to participate in this research study if:

• You have had a Stroke at least 3 months ago, and
• Experience severe persisting fatigue.

---

For more information and to register your interest in this clinical research study, contact:

Susan Day, Research Coordinator (Northern Sydney Local Health District)

Phone: (02) 9463 1732 | Email: susan.day@health.nsw.gov.au